NVAX Aug 2024 17.500 call
- CNW Group
Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for authorization with Health Canada for its 2024-2025 Formula COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older. The submission follows the National Advisory Committee on Immunization (NACI) guidance to use the latest selected strain and the guidance from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and World Heal
- Insider Monkey
Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
We recently published a list of the 10 Stocks to Buy and Sell Before the Third Quarter 2024 According to Jim Cramer. Since Novavax Inc (NASDAQ:NVAX) ranks 10th on the list, it deserves a deeper look. Jim Cramer in a latest program discussed the changing consumer trends in the US, wondering whether the consumer is just […]
- Zacks
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.
